Hormonal acne is one of the most common and persistent forms of acne, affecting both adolescents and adults, particularly women. Many people automatically associate this type of acne with having “hormonal imbalances”. However, in most cases, hormone levels are completely normal.

The issue usually lies not in the quantity of hormones, but in how the skin responds to them (specifically, in the sensitivity of the sebaceous gland to androgens).

In this context, a new therapeutic option has emerged: topical clascoterone 1% is the first locally administered anti-androgen approved for the treatment of acne.

Why do androgens influence acne?

Androgens are hormones that stimulate the sebaceous gland and increase sebum production. When sebum production is excessive:

  • Pore obstruction is promoted.
  • Proliferation of Cutibacterium acnes increases.
  • Inflammatory mechanisms are activated.

The result is the development of inflammatory lesions (particularly along the jawline, chin and neck)

For this reason, blocking androgen activity at the cutaneous level is a logical strategy in the treatment of acne with a hormonal component.

How does clascoterone act on the skin?

Clascoterone is a topical anti-androgen that works by blocking the androgen receptor within the sebaceous gland.

It is important to understand that:

  • It does not reduce circulating hormone levels.
  • It does not alter systemic hormonal balance.
  • It acts only in the skin where it is applied.

In this way, it reduces sebum production and decreases acne-related inflammation, with minimal systemic absorption.

What efficacy has been demonstrated in clinical studies?

According to a review published in the Journal of Clinical and Aesthetic Dermatology (2026), clascoterone 1% cream is currently the only topical anti-androgen approved by the FDA for the treatment of acne in patients aged 12 years and older.

In clinical trials involving more than 1,400 patients with moderate to severe acne, twice-daily application for 12 weeks achieved:

  • Significant reduction in inflammatory and non-inflammatory lesions.
  • Global improvement as assessed by investigators.
  • A favourable tolerability profile.

Detected systemic levels were minimal, reinforcing its safety profile.

Is it safe? Does it have hormonal effects?

One of the main concerns among patients is whether it may cause hormonal effects similar to those associated with oral treatments.

In the available studies:

  • Adverse effects were comparable to placebo.
  • The most commonly observed reactions were mild local erythema or dryness.
  • No clinically relevant systemic hormonal effects were detected.

This makes it an attractive alternative for patients who wish to avoid oral medication.

Which patients may benefit most?

Clascoterone may be particularly useful in:

  • Adult women with persistent acne.
  • Patients with premenstrual flares.
  • Individuals who do not tolerate oral contraceptives.
  • Patients who prefer to avoid systemic treatment.
  • Men with inflammatory acne.

It does not replace isotretinoin in severe acne, nor does it always match the efficacy of oral spironolactone in moderate to severe cases. However, it provides a safe, localised alternative.

It may also be combined with topical retinoids or other standard treatments.

What about topical spironolactone?

Various topical formulations of spironolactone have been studied (5% cream, 5% gel, 2% solution or 1% nanogel).

Although some data suggest a reduction in lesion count, studies are small and heterogeneous. At present:

  • It is not commercially approved.
  • It requires compounding.
  • Robust data on systemic absorption are lacking.

Its use therefore remains limited compared with clascoterone.

So, is clascoterone worth considering?

Topical hormonal therapies represent a meaningful advance in acne management, particularly in patients with a clear androgenic component but normal laboratory hormone levels.

Topical clascoterone stands out for:

  • Scientific evidence.
  • A favourable safety profile.
  • Localised mechanism of action.
  • Suitability for both men and women.

Nevertheless, treatment selection should always be individualised according to:

  • Acne type and severity.
  • Patient age and sex.
  • Medical history.
  • Previous treatments.
  • Therapeutic expectations.

A dermatological assessment is essential to determine whether a topical anti-androgen is the most appropriate strategy in each individual case.